Listed as number three in pharma sales, GlaxoSmithKline has had some rough luck thanks in part to the diabetes drug Avandia, which has been pulled out of Europe and restricted in the U.S after global side effect concerns since 2007. The company cut its losses on the drug, writing off $233 million in supplies and eliminating its marketing efforts of the drug.

The company has racked up some charges against its earnings, including over $6 billion in the fourth quarter of 2010 from Avandia and marketing settlements. GSK settled 10,000 Avandia lawsuits for a combined $460 million. Also, the company hit number three on FiercePharma's Top Layoffs of 2010 list with 5,201 jobs lost. While other companies look towards more spinoffs, GSK has focused on emerging markets as its ticket to higher revenue. It purchased Laboratorios Phoenix in 2009 and China's MeiRui in 2010; the UK-based company said the impact of its layoffs would be masked by more job opportunities in Asia and South America.

In early 2011, GSK and Human Genome Sciences gained FDA approval for Benlysta, the first new lupus treatment in more than 50 years, and experts believe it could be a $3 billion to $5 billion worldwide sales heyday for the partnership. But the FDA denied an extended approval and a potential $1 billion in sales to GSK from the prostate drug Avodart. While the drug was effective against low-risk malignant tumors, it potentially heightened the risk of developing more aggressive tumors.

GSK spun off its HIV treatments into ViiV Healthcare in 2009, combining it with Pfizer's former R&D efforts in the field. ViiV markets Ziagen, Trizivir, Epzicom and abacavir as part of its suite of drugs for HIV/AIDS.

Tag:

GlaxoSmithKline

Latest Headlines

Latest Headlines

GSK misses survival endpoint with Tykerb-Herceptin pairing

Glaxo announced at ASCO on Sunday that in a Phase III study, Tykerb and Herceptin failed to improve  disease-free survival in HER2-positive early breast cancer patients over  Herceptin on its own.

GlaxoSmithKline opens a new chapter in cancer R&D with pioneering TCR pact

GlaxoSmithKline's oncology division is retooling and adding a new focus on the emerging field of T-cell engineering in immuno-oncology. And in the process the pharma giant is sending a clear message that it still sees a bright future for itself in cancer drug research.

Glaxo seeks buyers for older products worth up to $12.6B

GlaxoSmithKline has already made some moves to sell off some of its older meds. But now, it's making more that could end up much, much bigger.

GSK India exec sees growth fueled by Novartis vaccine assets

GlaxoSmithKline's emerging-market vaccines sales have seen better days, thanks to a $489 million bribery probe that recently led to the indictment of the company's former China head. But according to a local exec, good times are ahead for Glaxo's vaccines unit in India--and the company's recent pickup of Novartis' non-flu vaccine assets will help it get there.

GlaxoSmithKline's India unit eyes sales growth after Novartis vax deal

According to a local exec, good times are ahead for Glaxo's vaccines unit in India--and the company's recent pickup of Novartis' non-flu vaccine assets will help it get there.

Top 10 best-selling vaccines of 2013

The vaccine market has long been dominated by the Big 3--Sanofi, Merck and GlaxoSmithKline--with Pfizer and Novartis trailing the trio on the list of revenue-generators. But things are changing at the top.

ASCO preview: What's the outlook for cancer vaccines?

The cancer vaccine field has seen its share of late-stage disappointments and outright flops, but a number of hopefuls are lining up to present new research backing their experimental shots at this year's upcoming American Society of Clinical Oncology Annual Meeting in Chicago.

GlaxoSmithKline to head tuberculosis drug discovery initiative

As rates of drug-resistant tuberculosis rise across the globe, GlaxoSmithKline is partnering with Switzerland's BioVersys and France's University of Lille to develop a preclinical candidate against the airborne disease.

U.K. fraud police launch GlaxoSmithKline probe in wake of China corruption charges

Ever since China began investigating GlaxoSmithKline's business practices last year, analysts have feared the British drug giant could get in big trouble in its home country, too. Their worries appear to be justified as Britain's Serious Fraud Office said today it had opened a criminal investigation.

Pharma profit margins sag in China under weight of corruption crackdown

As China steps up its investigations into alleged corruption at GlaxoSmithKline and other multinational pharmaceutical companies, China-based healthcare companies are also taking a major hit.